NewAmsterdam Financial Statements From 2010 to 2025

NAMSW Stock   12.25  0.43  3.39%   
NewAmsterdam Pharma financial statements provide useful quarterly and yearly information to potential NewAmsterdam Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NewAmsterdam Pharma financial statements helps investors assess NewAmsterdam Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NewAmsterdam Pharma's valuation are summarized below:
Gross Profit
45.6 M
Revenue
45.6 M
Quarterly Revenue Growth
14.905
Revenue Per Share
0.483
There are over one hundred nineteen available fundamental ratios for NewAmsterdam Pharma, which can be analyzed over time and compared to other ratios. All traders should should check NewAmsterdam Pharma's last-minute fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable.

NewAmsterdam Pharma Total Revenue

33.93 Million

Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 17.7 M, Interest Income of 17.7 M or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 33.94, Dividend Yield of 0.0 or PTB Ratio of 3.36. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Pharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets907.9 M864.6 M175.8 M
Slightly volatile
Short and Long Term Debt Total425.6 K448 K8.1 M
Slightly volatile
Other Current Liabilities100.5 M95.7 M14.9 M
Slightly volatile
Total Current Liabilities112.3 M106.9 M28.5 M
Slightly volatile
Property Plant And Equipment Net706.6 K673 K121.7 K
Slightly volatile
Accounts PayableM4.7 M3.4 M
Slightly volatile
Cash810.3 M771.7 M156.3 M
Slightly volatile
Non Current Assets Total1.1 M1.2 M5.4 M
Pretty Stable
Cash And Short Term Investments875.9 M834.2 M164.3 M
Slightly volatile
Common Stock Shares Outstanding50.8 M94.4 M28.7 M
Slightly volatile
Liabilities And Stockholders Equity907.9 M864.6 M175.8 M
Slightly volatile
Non Current Liabilities Total191.9 K202 K8.1 M
Slightly volatile
Other Current Assets30.7 M29.2 M6.1 M
Slightly volatile
Total Liabilities112.5 M107.1 M29.8 M
Slightly volatile
Net Invested Capital795.4 M757.5 M154 M
Slightly volatile
Property Plant And Equipment Gross706.6 K673 K127.9 K
Slightly volatile
Short and Long Term Debt9.3 M10.5 M11.4 M
Slightly volatile
Total Current Assets906.6 M863.4 M170.3 M
Slightly volatile
Capital Stock12.8 M13.4 M46.7 M
Slightly volatile
Short Term Debt467.4 K492 K8.1 M
Slightly volatile
Common Stock12.8 M13.4 M46.7 M
Slightly volatile
Current Deferred Revenue8.7 MMM
Slightly volatile
Net Receivables2.3 M1.7 M4.1 M
Slightly volatile
Accumulated Other Comprehensive Income3.9 M4.5 M1.5 M
Slightly volatile
Good Will186.5 K209.8 K228.7 K
Slightly volatile
Intangible Assets507.3 K534 K67.5 M
Slightly volatile
Other Assets22.4 K25.1 K27.4 K
Slightly volatile
Other Stockholder Equity731.7 M739.6 M608.9 M
Slightly volatile

NewAmsterdam Pharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative74 M70.4 M13 M
Slightly volatile
Selling And Marketing Expenses4.9 M4.7 MM
Slightly volatile
Other Operating Expenses124 M221.9 M46.4 M
Slightly volatile
Research Development92.7 M151.4 M34.7 M
Slightly volatile
Total Operating Expenses127 M221.9 M47.4 M
Slightly volatile
Reconciled Depreciation118.7 K113 K23.6 K
Slightly volatile
Cost Of Revenue47.5 K51.1 K24.3 K
Slightly volatile

NewAmsterdam Pharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow191.8 M340.4 M68 M
Slightly volatile
Depreciation118.7 K113 K23.6 K
Slightly volatile
Capital Expenditures705.6 K672 K98.6 K
Slightly volatile
Total Cash From Financing Activities692.5 M659.5 M120.6 M
Slightly volatile
End Period Cash Flow810.3 M771.7 M156.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio33.9453.223111.6933
Slightly volatile
Days Sales Outstanding24.6748.4214.3312
Slightly volatile
Stock Based Compensation To Revenue0.720.73790.2463
Slightly volatile
Capex To Depreciation6.245.94691.875
Slightly volatile
Sales General And Administrative To Revenue1.961.54611.9821
Slightly volatile
Research And Ddevelopement To Revenue4.443.3231.9522
Slightly volatile
Capex To Revenue0.01550.01470.0021
Slightly volatile
Cash Per Share6.338.84073.1436
Slightly volatile
Intangibles To Total Assets6.0E-46.0E-40.1272
Slightly volatile
Current Ratio5.58.07552.94
Slightly volatile
Receivables Turnover7.417.839.0189
Slightly volatile
Capex Per Share0.00750.00710.0015
Slightly volatile
Revenue Per Share0.460.48294.1772
Slightly volatile
Interest Debt Per Share0.00450.00470.458
Slightly volatile
Debt To Assets5.0E-45.0E-40.8679
Slightly volatile
Operating Cycle24.6748.4214.3312
Slightly volatile
Ebt Per Ebit1.751.37051.4559
Slightly volatile
Long Term Debt To Capitalization2.0E-42.0E-43.0E-4
Slightly volatile
Total Debt To Capitalization6.0E-46.0E-40.9924
Slightly volatile
Quick Ratio5.58.07552.9399
Slightly volatile
Net Income Per E B T1.161.01.1011
Pretty Stable
Cash Ratio5.187.21812.732
Slightly volatile
Cash Conversion Cycle24.6748.4214.3312
Slightly volatile
Days Of Sales Outstanding24.6748.4214.3312
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00420.9892
Slightly volatile
Fixed Asset Turnover64.3267.7013557
Slightly volatile
Debt Ratio5.0E-45.0E-40.8679
Slightly volatile
Price Sales Ratio33.9453.223111.6933
Slightly volatile
Asset Turnover0.0990.05270.1584
Slightly volatile

NewAmsterdam Pharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B2.2 B599.2 M
Slightly volatile

NewAmsterdam Fundamental Market Drivers

Cash And Short Term Investments834.2 M

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred RevenueM8.7 M
Total Revenue45.6 M33.9 M
Cost Of Revenue51.1 K47.5 K
Stock Based Compensation To Revenue 0.74  0.72 
Sales General And Administrative To Revenue 1.55  1.96 
Research And Ddevelopement To Revenue 3.32  4.44 
Capex To Revenue 0.01  0.02 
Revenue Per Share 0.48  0.46 
Ebit Per Revenue(3.87)(4.06)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.